Virus therapy takes on hard-to-treat cancers in early trial
NCT ID NCT06215846
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 30 times
Summary
This early-phase study tests a new treatment called BioTTT001, a modified virus designed to infect and kill cancer cells while boosting the immune system. It involves 12 adults with advanced solid tumors (like head and neck, colorectal, skin, or cervical cancer) who have not responded to standard treatments. The main goal is to check the therapy's safety and find the right dose, not to cure the disease at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The First Affiliated Hospital of China Medical Univeristy
Shenyang, Liaoning, China
Conditions
Explore the condition pages connected to this study.